Eczema drug interaction study completed – no cure, just safety data

NCT ID NCT05891119

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-phase study looked at how rocatinlimab changes the way the body processes certain other medications in 21 adults with moderate to severe atopic dermatitis (eczema). Participants received a cocktail of common drugs before and after rocatinlimab to measure differences in drug levels. The goal was to gather safety and interaction information, not to treat the disease. No direct benefit to participants was intended.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Accel Research Sites (ACR)

    DeLand, Florida, 32720-3134, United States

  • Axis Clinicals, LCC

    Dilworth, Minnesota, 56529, United States

  • DermDox Dermatology Centers, PC - Camp Hill

    Camp Hill, Pennsylvania, 17011, United States

  • DermDox Dermatology Centers, PC - Sugarloaf

    Nashville, Tennessee, 37203-1632, United States

  • Direct Helpers Research Center (DHRC)

    Hialeah, Florida, 33012-3618, United States

  • Velocity Clinical Research -Spartanburg

    Spartanburg, South Carolina, 29303-4225, United States

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California, 91606-1570, United States

Conditions

Explore the condition pages connected to this study.